文献速递前列腺癌

BHC80基因RNA剪接促进神经内分泌前列腺癌进展

RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
PubMed 文献 · Eur Urol · 2019-03-23

研究比较了前列腺腺癌(AdPC)与治疗诱导的神经内分泌前列腺癌(t-NEPC)患者肿瘤中BHC80剪接变体(BHC80-1和BHC80-2)的表达,并在t-NEPC细胞和异种移植模型中探讨了BHC80基因RNA剪接的调控机制及剪接变体介导的信号通路。全转录组分析发现BHC80-2变体在t-NEPC中高表达,BHC80-2定位在细胞质中触发MyD88-p38-TTP通路,增加多种促肿瘤细胞因子的RNA稳定性,刺激细胞增殖和肿瘤进展,且不诱导神经内分泌分化。阻断BHC80-2调控的MyD88信号可抑制多种t-NEPC细胞球体和异种移植模型的生长。

要点

  • BHC80-2变体在t-NEPC中高表达,通过MyD88-p38-TTP通路增加促肿瘤细胞因子RNA稳定性。
  • BHC80-2不诱导神经内分泌分化,但以不依赖雄激素受体信号的方式刺激细胞增殖和肿瘤进展。
  • 阻断BHC80-2调控的MyD88信号可抑制多种t-NEPC细胞球体和异种移植模型的生长。

核心结论

  • BHC80-2通过替代RNA剪接获得功能,激活癌细胞的免疫反应,促进t-NEPC发展。
  • 靶向BHC80-2-MyD88信号通路可能为治疗t-NEPC提供途径(原文为原理验证)。

研究设计与样本

  • 比较AdPC与t-NEPC患者肿瘤中BHC80剪接变体(BHC80-1和BHC80-2)的表达。
  • 研究BHC80基因RNA剪接的调控机制,并在t-NEPC细胞和异种移植模型中探讨BHC80剪接变体介导的信号通路。

主要发现

  • 全转录组分析鉴定出BHC80-2变体在t-NEPC中高表达。
  • BHC80-2定位在细胞质中触发MyD88-p38-TTP通路,导致多种促肿瘤细胞因子的RNA稳定性增加。
  • BHC80-2不诱导癌细胞的神经内分泌分化,但刺激细胞增殖和肿瘤进展,且不依赖雄激素受体信号。
  • 阻断BHC80-2调控的MyD88信号可抑制多种t-NEPC细胞球体和异种移植模型的生长。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate adenocarcinoma (AdPC) progression to treatment-induced neuroendocrine prostate cancer (t-NEPC) is associated with poor patient survival. While AdPC and t-NEPC share similar genomes, they possess distinct transcriptomes, suggesting that RNA splicing and epigenetic mechanisms may regulate t-NEPC development. OBJECTIVE: To characterize the role of alternative RNA splicing of the histone demethylase BHC80 during t-NEPC progression. DESIGN, SETTING, AND PARTICIPANTS: The expression of BHC80 splice variants (BHC80-1 and BHC80-2) were compared between AdPC and t-NEPC patient tumors. Regulatory mechanisms of RNA splicing of the BHC80 gene were studied, and the signal pathways mediated by BHC80 splice variants were investigated in t-NEPC cell and xenograft models. RESULTS: Global transcriptome analyses identified that the BHC80-2 variant is highly expressed in t-NEPC. Compared with the known histone demethylation activities of the BHC80 gene, we discovered a novel nonepigenetic action of BHC80-2, whereby BHC80-2 is localized in the cytoplasm to trigger the MyD88-p38-TTP pathway, which results in increased RNA stability of multiple tumor-promoting cytokines. While BHC80-2 does not induce neuroendocrine differentiation of cancer cells, it stimulates cell proliferation and tumor progression independent of androgen receptor signaling. Blockade of BHC80-2-regulated MyD88 signaling suppresses growth of several t-NEPC cell spheroid and xenograft models. CONCLUSIONS: Gain of function of BHC80-2 through alternative RNA splicing activates immune responses of cancer cells to promote t-NEPC development. PATIENT SUMMARY: The main obstacle to develop effective therapies for patients with t-NEPC is the lack of understanding on how t-NEPC is developed. Our study not only identifies a previously unknown BHC80-2-MyD88 signaling pathway that plays an important role during t-NEPC development, but also provides a proof of principle that targeting this signal pathway may offer an avenue to treat t-NEPC.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Li Y, Xie N, Chen R, et al. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. Eur Urol. 2019. PMID: 30910347. doi:10.1016/j.eururo.2019.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。